CITI PHARMA LIMITED
NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an Extraordinary General Meeting (the "EOGM") of the members of Citi Pharma Limited (the "Company") will be held on Friday, 18 September 2026 at 11:00 a.m. at the Company's Head Office situated at 588-Q, Johar Town, Lahore, to transact the following special business:

ORDINARY BUSINESS

1. To confirm the minutes of last Extra Ordinary General Meeting of the Company held on July 08, 2026.

SPECIAL BUSINESS

2. To consider and if thought fit pass with or without modification the following Special Resolution:

SPECIAL RESOLUTION

ALTERATION OF MEMORANDUM OF ASSOCIATION

To consider and, if thought fit, to pass the following resolution as a Special Resolution pursuant to Section 32(1)(c) and other applicable provisions of the Companies Act, 2017:

"**RESOLVED THAT** pursuant to Section 32(1)(c) and other applicable provisions of the Companies Act, 2017, and subject to confirmation by the Securities and Exchange Commission of Pakistan and such other approvals as may be required under applicable law, the Memorandum of Association of the Company be and is hereby altered by inserting a new Clause No. 38 under Clause III thereof, after the existing Clause No. 37, in the following terms:

Clause No. 38. To carry on, in Pakistan and abroad, the full spectrum of cannabis-related, industrial hemp, medicinal cannabis and marijuana businesses and allied activities, whether as principal, agent, contractor, licensee, consultant, developer, operator or otherwise, including without limitation: (i) the cultivation, growing, breeding, research, propagation, development, harvesting and production of industrial hemp, medicinal cannabis (controlled and open field), marijuana and other cannabis varieties; (ii) the processing, extraction, refining, purification, isolation, concentration, distillation, formulation and compounding of cannabis, hemp and marijuana and their derivatives, extracts, oils, resins, isolates, tinctures, distillates, cannabinoids (including CBD, THC and other cannabinoids), terpenes, flavonoids, proteins and other bioactive compounds and by-products thereof; (iii) the manufacture, formulation, compounding, blending, packaging, repackaging, labeling and re-labeling of pharmaceutical, nutraceutical, cosmeceutical, dietary supplement, herbal, veterinary, food, beverage, industrial, chemical and other products containing or derived from cannabis, hemp or marijuana; (iv) research and development, clinical and pre-clinical studies, agronomic research, genetic development, biotechnology, plant tissue culture, product development and innovation in relation to cannabis, hemp and marijuana and their derivatives; (v) laboratory testing, quality control, analytical testing, certification and other testing services; (vi) establishment and operation of rehabilitation centers, medical, healthcare and other institutions and facilities for treatment, care, education, training and related services in connection with cannabis, hemp or marijuana-based therapies or products; (vii) storage, warehousing, cold storage, inventory management and other storage services; (viii) transportation, logistics, freight forwarding and supply chain management; (ix) import, export, purchase, sale, distribution, marketing, branding, promotion, advertising and otherwise dealing in cannabis, hemp, marijuana and all types of products, derivatives, extracts, compounds, formulations, preparations and by-products thereof, and in all related machinery, equipment, raw materials, consumables and services; (x) import of seeds, genetics, plant material, equipment, machinery and other inputs and

export of products and by-products and securing and holding export licenses or other export authorizations; (xi) to act as growers, processors, manufacturers, traders, suppliers, stockists, wholesalers, retailers, distributors, marketers, export agents, importers, exporters, consultants, advisors, franchisees, licensees or otherwise in relation to any of the foregoing; and (xii) to undertake any other activity ancillary, incidental,
connected or conducive to the attainment of the above objects.

PROVIDED THAT all the foregoing activities shall be carried on strictly in accordance with all applicable laws and regulations and upon obtaining such licenses, registrations, permissions and authorizations as may be required from the Cannabis Control and Regulatory Authority (CCRA), Drug Regulatory Authority of Pakistan (DRAP) and/or any other competent Government, regulatory or licensing authority, as may be applicable from time to time.

RESOLVED FURTHER THAT the Chief Executive Officer/ Company Secretary be and are hereby jointly or severally authorized to make such modifications, additions, deletions or amendments to the aforesaid clause and the Memorandum of Association as may be required or suggested by the Securities and Exchange Commission of Pakistan, CCRA, Pakistan Stock Exchange Limited or any other competent authority, and to do all acts, deeds and things necessary or incidental for giving effect to this resolution."

OTHER BUSINESS

3. To transact any other business that may be placed before the meeting with the permission of the Chair.

(Attached to this notice is a Statement of Material Facts covering the abovementioned Special Business, as required under section 134(3) of the Companies Act, 2017)

By Order of the Board

Rashid

Muhammad Rasheed Alam
Company Secretary
Citi Pharma Limited

CITI PHARMA LIMITED
citi PHARMA

Place: Lahore
Date: 28 August 2026

Notes:

1. Closure of Share Transfer Books

The share transfer books will remain closed from September 12,2026 to September 18, 2026 (both days inclusive). Transfers received in order at the office of Company's Share Registrar, M/s F.D Registrar Services (Pvt) Ltd, 17th Floor Saima Trade Tower-A II Chundrigar Road Karachi at the close of business on September 11, 2026 shall be treated in time for the purpose of attending the EOGM.

2. Participation in the EOGM via physical presence including through proxy:

Members whose names appear in the Register of Members as of September 11, 2026, are entitled to attend and vote at the EOGM. A member entitled to attend and vote at the EOGM is entitled to appoint a proxy to attend, speak and vote for him/her. The proxy need not be a member of the Company:

An Instrument of proxy applicable for the EOGM is being provided with the Notice sent to the members. Proxy form may also be downloaded from the Company's website: www.citipharma.com.pk. An instrument of proxy and the power of attorney or other authority, if any, under which it is signed, or a certified true copy of such power or authority duly notarized must, to be valid, be received at the Company's Head Office: 588 Q Block M.A Johar Town Lahore(attention to the Company Secretary) or email at corporate@citipharma.com.pk not less than 48 hours before the time of EOGM.

Members having physical shareholding are requested to submit a copy of their Computerized National Identity Card (CNIC) at the registered address of the Company's Share Registrar M/s F.D Registrar Services (Pvt) Ltd, 17th Floor Saima Trade Tower-A II Chundrigar Road Karachi. CDC account holders may submit the same to their respective CDC Participant/ Stockbroker / Investor Account Services.

If a member appoints more than one proxy and more than one instrument of proxy Is deposited by a member, all such instruments of proxy shall be rendered invalid.

3. Participation in the EOGM through Video conferencing:

a. Members interested in attending / participating in the EOGM through video link facility are hereby advised to get themselves registered with the Company by providing the following Information through email sent to corporate@citipharma.com.pk at the earliest, but not later than 48 hours before the time of the EOGM i.e. before 11:00 a.m. on September 16, 2026.

i. Name of Member;
ii. CNIC / NTN No.;
iii. Folio No./ CDC IAS No.;
iv. Cell No.; and
v. Email address.

vi. The online meeting link and login credentials will be shared with only those members who provide their intent to attend the meeting containing at the required particular's as mentioned above on or before September,16, 2026 by 11:00 a.m.

b. The login facility will remain open from 10:50 a.m. on September 18, 2026 till the end of EOGM.

c. An individual beneficial owner of the shares must share his/her original CNIC or Passport, Account and Participant's ID numbers to prove his/ her identity. A representative of corporate members must bring the Board of Directors' Resolution and/or Power of Attorney and the specimen signature of the nominee. CDC account holders will further have to follow the guidelines as laid down in Circular No. 1 dated January 26, 2000 issued by the Securities and Exchange Commission of Pakistan.

4. Circulation of Notice to the shareholders through Email:

Moreover, as per the SECP's notification vide SRO 452(1)/2025, dated March 17, 2025, the notice of the EOGM shall be circulated to members through email in case email address has been provided by the respective member to the

Company regardless of the fact that the consent of the member to receive the notice through email has been received or not.

5. Change of Address

Members having physical shares are requested to notify changes in their address, if any, immediately to the Company's Share Registrar, M/s F.D Registrar Services (Pvt) Ltd, 17th Floor Saima Trade Tower-A II Chundrigar Road Karachi. CDC account holders may submit the same to their respective CDC Participant/ Stockbroker/ Investor Account Services

6. Polling on Special Business Resolutions:

The members are hereby notified that pursuant to Companies (Postal Ballot) Regulations, 2018 (the "Regulations"), as amended through Notification dated December 05, 2022, issued by the Securities and Exchange Commission of Pakistan ("SECP"), the SECP has directed all the listed companies to provide the right to vote through electronic voting facility and voting by post to the members on all businesses classified as special business.

Accordingly, members of the Company will be allowed to exercise their right to vote through electronic voting facility or voting by post for the special business in its forthcoming EOGM to be held on September 18, 2026 at 11:00 a.m. in accordance with the requirements and subject to the conditions contained in the aforesaid Regulations.

For the convenience of the Members, ballot paper is annexed to this notice and the same is also available on the Company's website at www.citipharma.com.pk for download.

1. Procedure for E-Voting:

i. Details of the e-voting facility will be shared through an e-mail with those members of the Company who have their valid CNIC numbers, cell numbers, and e-mail addresses available in the register of members of the Company by the close of business on September 11, 2026.

ii. The web address, login details, and password, will be communicated to members via email. The security codes will be communicated to members through SMS from the web portal of CDC Share Registrar Services Limited (being the e-voting service provider).

iii. Identity of the Members intending to cast vote through e-voting shall be authenticated through electronic signature or authentication for login.

iv. E-Voting lines will start from September 15,2026 and shall close on September 17, 2026 at 5:00 p.m. Members can cast their votes any time during this period. Once the vote on a resolution is cast by a Member, he/ she shall not be allowed to change It subsequently.

2. Procedure for Voting Through Postal Ballot:

The members shall ensure that duly filled and signed ballot paper, along with copy of Computerized National Identity Card (CNIC), should reach the Chairman of the meeting through post on the Company's head address at 588 Q Block Johar Town Lahore or email at Chairman@citipharma.com.pk. no later than one day before the EOGM on September 18, 2026, i.e. by September 17, 2026 during working hours (before 11:00 a.m.). The signature on the ballot paper shall match the signature on CNIC.

7. Appointment of Scrutinizer:

In accordance with Regulation No 11A of the Companies (Postal Ballot) Regulations, 2018, the Board of the Company has appointed M/s. Aslam Malik & CO, Chartered Accountants, to act as the Scrutinizer of the Company for Polling on the Special Business, and to undertake other responsibilities as defined In Regulation No. 11A.

8. Unclaimed Dividend and Bonus Shares:

Shareholders, who by any reason, could not claim their dividend or bonus shares or did not collect their physical shares, are advised to contact our Share Registrar i.e., M/s F.D Registrar Services (Pvt) Ltd, 17th Floor Saima Trade Tower-A II Chundrigar Road Karachi to collect/enquire about their unclaimed dividend or pending shares, if any.

Please note that-in compliance with Section 244 of the Companies Act 2017, after having completed the stipulated procedure, all dividend unclaimed tor a period of three years from the date due and payable shall be deposited to the credit of the Federal Government and in case of shares, shall be delivered to the Securities & Exchange Commission of Pakistan.

9. Conversion of physical shares in to Book-entry form:

In compliance with section 72 of the Companies Act 2017 and SECP's: Letter No. CSD/ED/Misc./2016-639-640 dated 26 March 2021, listed companies are required to replace existing physical shares issued by them into Book-Entry Form. In view of the above requirement shareholders of the Company having physical folios/ share certificates are requested to convert their Shares from physical form into Book-Entry Form as soon as possible.

Conversion of physical shares into Book-Entry Form would facilitate the shareholders in many way, including safe custody of shares, readily available market for instant sale and purchase of share, eliminate risk of loss & damage, easy & safe transfer with lesser formalities as compared to physical shares. The shareholders of the Company may contact Share Registrar of the Company ie F.D Registrar for assistance in conversion of physical shares into Book-Entry Form.

10. Others

In accordance with Section 185 of the Companies Act, 2017 and SRO 452(1)/2025, dated March 17, 2025, the SECP has directed to clearly stipulate that no gifts will be distributed at the EOGM.

STATEMENT OF MATERIAL FACTS
Under Section 134(3) of the Companies Act, 2017

This Statement of Material Facts is annexed to and forms part of the Notice of the Extraordinary General Meeting of Citi Pharma Limited to be held on Friday, 18 September 2026 at 11:00 a.m. The special business relates to the proposed alteration of the Memorandum of Association under Section 32(1)(c) of the Companies Act, 2017. The disclosures are made in accordance with Section 134(3) of the Companies Act, 2017 and S.R.O. 423(I)/2018, insofar as applicable.

1. BACKGROUND

1. The Company is presently engaged, inter alia, in the business of manufacturing, processing, trading and dealing in pharmaceuticals, chemicals and allied products, as set out in Clause III of its Memorandum of Association ("MOA").

2. In view of the emerging regulatory framework for the cannabis sector in Pakistan and the opportunities presented by the sector, the Board of Directors considered it appropriate to expand the scope of the Company's objects to include a broad range of cannabis-related, industrial hemp, medicinal cannabis, marijuana and allied activities.

3. The Company submitted an application dated 10 June 2026 and subsequently provided supporting data and information vide email dated 12 August 2026 to the Cannabis Control and Regulatory Authority ("CCRA"), Cabinet Division, Government of Pakistan, seeking a No Objection Certificate ("NOC") for amendment of the Company's MOA to include such activities.

4. The CCRA, vide its letter No. F.10/2/Lic/CCRA/2026-280 dated 20 August 2026, issued an NOC confirming that it has no objection to the Company proceeding with the Securities and Exchange Commission of Pakistan ("SECP") for amendment of its MOA for inclusion of cannabis-related vertically integrated business activities, subject to the terms and conditions stated therein.

2. RATIONALE FOR THE PROPOSED AMENDMENT

5. The proposed amendment is intended to enable the Company, subject to applicable laws and regulatory approvals, to pursue opportunities in the regulated cannabis, industrial hemp and allied sectors and to leverage its existing pharmaceutical manufacturing, technical and distribution capabilities.

6. The Company is pursuing a cumulative licensing strategy covering, among other activities, industrial hemp cultivation, medicinal cannabis cultivation (controlled and open field), hemp processing, cannabis extraction, pharmaceutical manufacturing, synthetic/biosynthetic CBD, research and development, laboratory testing, rehabilitation and medical institutions, storage and warehousing, transportation and logistics, import of seeds/genetics and export activities, together with other allied activities.

7. The proposed alteration is intended to provide the Company with sufficient scope and flexibility to undertake, develop and expand such activities and related ancillary businesses as may be permissible under the applicable regulatory framework, without requiring repeated amendments to the MOA for each ancillary or related activity.

8. The proposed alteration is not intended to change the Company's existing principal line of business. The Company's existing pharmaceutical business will continue, while the proposed Clause No. 38 will constitute an additional business object.

3. COMPARATIVE ANALYSIS OF EXISTING AND PROPOSED PROVISION

Existing Provision	Proposed Alteration	Reason / Justification
Clause III of the MOA contains the Company's existing objects and presently concludes with Clause No. 37.	Insertion of a new Clause No. 38 under Clause III, after existing Clause No. 37, covering a broad range of cannabis-related, industrial hemp, medicinal cannabis, marijuana and allied activities, subject to applicable laws and regulatory approvals.	To broaden the Company's objects so that, subject to regulatory approvals, the Company may pursue its proposed cumulative licensing strategy and related business opportunities in the regulated cannabis, industrial hemp and allied sectors.

4. NATURE AND EFFECT OF THE PROPOSED AMENDMENT

9. The proposed amendment is enabling in nature. The new Clause No. 38 will provide the Company with the corporate capacity to undertake the activities described therein, subject always to applicable laws, licences, registrations, permissions, approvals and authorisations.

10. The detailed scope of the proposed activities is set out in the proposed Clause No. 38 reproduced in the Special Resolution forming part of the Notice of the EOGM. The proposed Clause No. 38 is deliberately broad to accommodate the Company's proposed cumulative licensing strategy and related future business opportunities. The complete draft amended Memorandum of Association incorporating the proposed Clause No. 38 shall be available for inspection by the members at the Head Office of the Company during business hours up to the date of the EOGM.

11. The proposed amendment does not, by itself, confer upon the Company any operational, cultivation, processing, manufacturing or other licensing right under the Cannabis Control and Regulatory Authority Act, 2024 or any other applicable law. The Company shall undertake any regulated activity only after obtaining such licences, registrations, permissions, approvals and authorisations as may be required from the CCRA, DRAP and/or any other competent authority.

5. REGULATORY POSITION AND APPROVALS REQUIRED

12. The proposed alteration of the MOA falls within Section 32(1)(c) of the Companies Act, 2017, as the proposed business activities are subject to licence, registration, permission or approval under applicable law. Accordingly, the proposed alteration is to be approved by the members by way of Special Resolution.

13. In accordance with Section 32(2) of the Companies Act, 2017, the alteration under Section 32(1)(c) shall not take effect until confirmed by the Securities and Exchange Commission of Pakistan.

14. The Company has obtained the CCRA NOC for proceeding with the amendment of its MOA. The NOC is an approval for the corporate process relating to the MOA amendment and does not itself constitute an operational or business licence. Any licence, registration, permission or approval required for commencement of the proposed activities shall be obtained separately from the CCRA and/or other competent authorities, as applicable.

15. Following approval of the Special Resolution, the Company shall make the requisite filings with the SECP and undertake such further corporate and regulatory formalities as may be required under the Companies Act, 2017 and applicable regulations.

6. EFFECT ON THE COMPANY AND ITS MEMBERS

16. The proposed alteration will expand the scope of activities which the Company may undertake, subject to applicable regulatory approvals. It does not, by itself, commence or authorize the commencement of any regulated cannabis-related operations.

17. The proposed alteration is expected to provide the Company with greater flexibility to explore and develop opportunities in the regulated cannabis, industrial hemp and allied sectors and to utilize its existing pharmaceutical and related capabilities. The proposed alteration does not, by itself, alter the rights or liabilities of the members of the Company.

7. INTEREST OF DIRECTORS AND KEY EXECUTIVES

18. None of the Directors, Chief Executive or their relatives has any interest, financial or otherwise, in the proposed Special Resolution, except to the extent of their respective shareholding in the Company, if any, which interest is common to the members generally and is not different in nature or extent from the interest of other members.

19. The Directors and shareholders referred to in the CCRA NOC are identified therein in connection with the regulatory application and issuance of the NOC. Such reference does not, by itself, indicate any special or differential interest of the said Directors in the proposed Special Resolution.

8. BOARD'S STATEMENT

20. The Board of Directors is of the opinion that the proposed alteration of the Memorandum of Association is in the interest of the Company and its members and is in accordance with the applicable provisions of the Companies Act, 2017 and the relevant regulatory framework, subject to confirmation by the Securities and Exchange Commission of Pakistan and obtaining such licences, permissions, registrations, approvals and authorisations as may be required under applicable law.

21. The Board of Directors recommends that the members approve the proposed Special Resolution.

9. DOCUMENTS AVAILABLE FOR INSPECTION

22. A copy of the CCRA NOC dated 20 August 2026 and the draft amended Memorandum of Association incorporating the proposed Clause No. 38 shall be available for inspection by the members at the Head Office of the Company during business hours from the date of the Notice until the date of the EOGM.

By Order of the Board

Muhammad Rasheed Alam
Company Secretary
Citi Pharma Limited

Place: Lahore
Dated: 28 August 2026

CITI PHARMA LIMITED
BALLOT PAPER FOR VOTING THROUGH POST

For voting through post for the Special Business at the Extraordinary General Meeting of Citi Pharma Limited to be held on **Friday, 18 September 2026 at 11:00 a.m. (PST)** at the **Head Office of Citi Pharma Limited, 588-Q, Johar Town, Lahore.**

Designated email address of the Chairman at which the duly filled in ballot paper may be sent: chairman@citipharma.com.pk

Name of shareholder/joint shareholder(s):	
Registered Address:	
Folio No./ CDC Participant/ Investor ID with sub-account No.	
Number of shares held	
CNIC, NICOP/Passport No. (In case of foreigner) (Copy to be attached)	
Additional Information and enclosures (In case of representative of body corporates, corporations and Federal Government)	
Name of Authorized Signatory:	
CNIC, NICOP/Passport No. (In case of foreigner) of Authorized Signatory - (Copy to be attached)	

I/we hereby exercise my/our vote in respect of the following special resolutions through postal ballot by giving my/our assent or dissent to the following resolutions by placing tick □ mark in the appropriate box below:

Special Resolution

ALTERATION OF MEMORANDUM OF ASSOCIATION

To consider and, if thought fit, pass the following resolution as a **Special Resolution pursuant to Section 32(1)(c) and other applicable provisions of the Companies Act, 2017**:

"RESOLVED THAT pursuant to Section 32(1)(c) and other applicable provisions of the Companies Act, 2017, and subject to confirmation by the Securities and Exchange Commission of Pakistan and such other approvals as may be required under applicable law, the Memorandum of Association of the Company be and is hereby altered by inserting a new Clause No. 38 under Clause III thereof, after the existing Clause No. 37, in the following terms:

Clause No. 38. To carry on, in Pakistan and abroad, the full spectrum of cannabis-related, industrial hemp, medicinal cannabis and marijuana businesses and allied activities, whether as principal, agent, contractor, licensee, consultant, developer, operator or otherwise, including without limitation: (i) the cultivation, growing, breeding, research, propagation, development, harvesting and production of industrial hemp, medicinal cannabis (controlled and open field), marijuana and other cannabis varieties; (ii) the processing, extraction, refining, purification, isolation, concentration, distillation, formulation and compounding of cannabis, hemp and marijuana and their derivatives, extracts, oils, resins, isolates, tinctures, distillates, cannabinoids (including CBD, THC and other cannabinoids), terpenes, flavonoids, proteins and other bioactive compounds and by-products thereof; (iii) the manufacture, formulation, compounding, blending, packaging, repackaging, labeling and re-labeling of pharmaceutical, nutraceutical, cosmeceutical, dietary supplement, herbal, veterinary, food, beverage, industrial, chemical and other products containing or derived from cannabis, hemp or marijuana; (iv) research and development, clinical and pre-clinical studies, agronomic research, genetic development, biotechnology, plant tissue culture, product development and innovation in relation to cannabis, hemp and marijuana and their derivatives; (v) laboratory testing, quality control, analytical testing, certification and other testing services; (vi) establishment and operation of rehabilitation centers, medical, healthcare and other institutions and facilities for treatment, care, education, training and related services in connection with cannabis, hemp or marijuana-based therapies or products; (vii) storage, warehousing, cold storage, inventory management and other storage services; (viii) transportation, logistics, freight forwarding and supply chain management; (ix) import, export, purchase, sale, distribution, marketing, branding, promotion, advertising and otherwise dealing in cannabis, hemp, marijuana and all types of products, derivatives, extracts, compounds, formulations, preparations and by-products thereof, and in all related machinery, equipment, raw materials, consumables and services; (x) import of seeds, genetics, plant material, equipment, machinery and other inputs and export of products and by-products and securing and holding export licenses or other export authorizations; (xi) to act as growers, processors, manufacturers, traders, suppliers, stockists, wholesalers, retailers, distributors, marketers, export agents, importers, exporters, consultants, advisors, franchisees, licensees or otherwise in relation to any of the foregoing; and (xii) to undertake any other activity ancillary, incidental, connected or conducive to the attainment of the above objects.

PROVIDED THAT all the foregoing activities shall be carried on strictly in accordance with all applicable laws and regulations and upon obtaining such licenses, registrations, permissions and authorizations as may be required from the Cannabis Control and Regulatory Authority (CCRA), Drug Regulatory Authority of Pakistan (DRAP) and/or any other competent Government, regulatory or licensing authority, as may be applicable from time to time.

I/we hereby exercise my/our vote in respect of above-mentioned special resolutions through postal ballot by conveying my/our assent or dissent to the said resolutions by placing tick mark in the appropriate box below:

Sr. No.	Nature and Description of resolutions	I/We assent to the Resolutions (FOR)	I/We dissent to the Resolutions (AGAINST)
1.	Special Resolution as per the above Agenda		

____
Shareholder/ Proxy holder Signature/Authorized Signatory
(In case of corporate entity, please affix company stamp)

Place:_______________Date: _________________

NOTES:

1. Duly filled postal ballots should be sent to the Chairman at 588 Q, Johar Town, Lahore or through email at: chairman@citipharma.com.pk
2. Copy of CNIC, NICOP/Passport (In case of foreigner) should be enclosed with the postal ballot form.
3. Postal Ballot form should reach the Chairman of the Meeting on or before 17 September 2026 up to 5:00 p.m. Any Postal Ballot received after this time/date, will not be considered for voting.
4. In case of a representative of a body corporate, corporation or Federal Government, the Ballot Paper form must be accompanied by a copy of the CNIC of an authorized person, an attested copy of Board Resolution/ Power of Attorney I Authorization Letter etc., in accordance with Section(s) 138 or 139 of the Companies Act, 2017 as applicable. In the case of foreign body corporate etc., all documents must be attested by the Consul General of Pakistan having jurisdiction over the member.
5. Signature on postal ballot should match with signature on CNIC, NICOP/Passport (In case of foreigner).
6. Incomplete, unsigned, incorrect, defaced, torn, mutilated, over written ballot paper will be rejected.
7. Ballot Papers form has also been placed on the website of the Company at: www.citipharma.com.pk Members may download the ballot paper from the website.
8. The proposed alteration of the Memorandum of Association is subject to confirmation by the Securities and Exchange Commission of Pakistan under Section 32(2) of the Companies Act, 2017 and shall not, by itself, confer any operational or licensing rights upon the Company.
9. Members are requested to read the Notice of EOGM and Statement of Material Facts carefully before exercising their vote.

Proxy Form

The Secretary
Citi Pharma Limited
588 Q, Johar Town, Lahore

I/We, ____ of _________________

shareholder of Citi Pharma Limited, holding ____________________ ordinary share(s) as per Register Folio No. / CDC Account No. ____________________ hereby appoint ____ of ______________ holding CNIC/Passport No. ______________________ or failing him/her hereby appoint ______________________________________ of _____________ holding CNIC/Passport No. ______________________ as my/our proxy, to attend and vote for me/us and on my/our behalf at the Extraordinary General Meeting of the Company, to be held on Friday, September 18, 2026 at 11:00 a.m. and/or any adjournment thereof.

Signed this ___ day of __ 2026

Witness 1:

Signature: ___________________
Name: ________________________
CNIC#: ________________________
Address: ______________________
____
____

[Signature should agree with the specimen signature registered with the Company]

____
Signature of Member(s)

Witness 2:
Signature: _________________
Name: _________________
CNIC#: _______________

Address:

Shareholder's Folio No.:
and/or CDC Participant I.D. No.:
and Sub-Account No.:
Shareholder's CNIC #:

Note:

1. The member Is requested:
   - i) To sign In the given box In the same style of signature as Is registered with the Company.
   - II) To write down his/her/their folio number.
   - 111) Attach an attested photocopy of their valid Computerized National Identity Card/Passport/Board Resolution and the copy of CNIC of the proxy, with this proxy form before submission.
2. In order to be valid, this proxy must be received at the registered office of the Company at least 48 hours before the time fixed for the meeting, duly completed In all respects.
3. CDS Shareholders or their proxies should bring their original computerized national Identity card or passport along with the Participant's ID Number and their Account Number to facilitate their Identification. Detailed procedure Is given In the notes to the notice of EOGM.